-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Japan's Ono Pharmaceutical Co., Ltd. announced that PD-1 monoantiphone Opdivo (nivolumab) combined anti-VEGF (vascular endoder growth factor) mono-bevacizumab and chemotherapy, treatment of non-small cell lung cancer Phase III clinical success.
Image source: Picture Source: In the ONO-4538-52/TASUKI-52 study, the Opdivo combination group (n s 275) was compared with a simple placebo combined with beva monotherapy and chemotherapy (placebo group: n s 275) in patients with IIIB/IV stage or recurrent non-squamous non-small cell lung cancer who were not suitable for radiotherapy.
analysis showed that the Opdivo group showed significant statistical improvement in the main endpoints of progression-free survival (PFS) compared to the placebo group, and no new safety issues were identified.
.